Nuvectis Pharma, Inc.
Close on Oct 19, 2026
- Market cap
- $444.64M
- P/E (TTM)
- –
- Dividend yield
- 0.00%
Earnings
Next report expected Nov 3, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 4, 2026 | Before market open | – | $-0.30 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 5, 2026 | Before market open | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 11, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 4, 2025 | Before market open | – | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 5, 2025 | Before market open | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 6, 2025 | Before market open | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 25, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 5, 2024 | Before market open | – | $-0.24 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 6, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 7, 2024 | Before market open | – | $-0.25 | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 5, 2024 | Before market open | – | – | – |
Press releases
Announcements Nuvectis Pharma filed with the SEC
Nuvectis Pharma Reports Second Quarter
Results of operations · EX-99.1 to Form 8-K
Nuvectis Pharma Announces Proposed Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
Nuvectis Pharma Announces Pricing of $100 Million
Material agreement · Other events · EX-99.2 to Form 8-K
Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for Two Potentially Best-In
Material agreement · Other events · EX-99.1 to Form 8-K
Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Nuvectis Pharma, Inc. Reports 2025 Financial Results and Business
Results of operations · EX-99.1 to Form 8-K
Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Nuvectis Pharma, Inc. Reports Second Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Nuvectis Pharma, Inc. Reports First Quarter 2025 Financial
Results of operations · EX-99.1 to Form 8-K
Nuvectis Pharma, Inc. Reports 2024
Results of operations · EX-99.1 to Form 8-K
Nuvectis Pharma Announces Proposed Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
Nuvectis Pharma Announces Pricing of $13.5 Million
Material agreement · Other events · EX-99.2 to Form 8-K
Nuvectis Pharma, Inc. Reports Third Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Nuvectis Pharma Announces Orphan Drug Designation Granted by the
Other events · EX-99.1 to Form 8-K
Nuvectis Pharma, Inc. Reports Second Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Nuvectis Pharma, Inc. Reports First Quarter 2024 Financial
Results of operations · EX-99.1 to Form 8-K
Nuvectis Pharma, Inc. Reports Fiscal Year 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Nuvectis Pharma, Inc. Reports Third Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
of the NXP900 Phase 1a Clinical Trial
Other events · EX-99.1 to Form 8-K
Nuvectis Pharma Announces Orphan Drug Designation
Other events · EX-99.1 to Form 8-K
Nuvectis Pharma, Inc. Reports Second Quarter
Results of operations · EX-99.1 to Form 8-K
Nuvectis Pharma Announces FDA Clearance of NXP900
Results of operations · EX-99.1 to Form 8-K
Nuvectis Pharma, Inc. Reports First Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Nuvectis Pharma, Inc. Reports Fiscal
Results of operations · EX-99.1 to Form 8-K
Nuvectis Pharma, Inc. Reports Third Quarter 2022 Financial
Results of operations · EX-99.1 to Form 8-K
Nuvectis Pharma, Inc. Reports Second Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Nuvectis Pharma, Inc. Announces Approximately
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Nuvectis Pharma, Inc. Reports First Quarter
Results of operations · EX-99.1 to Form 8-K
Nuvectis Pharma, Inc. Reports Fiscal Year 2021
Results of operations · Executive or director change · EX-99.1 to Form 8-K